Pyranopyridine Aldosterone Synthase Inhibitors With CYP11B2 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current aldosterone synthase inhibitors, such as LCI699 and Baxdrostat, lack sufficient selectivity for CYP11B2, leading to off-target effects on cortisol synthesis and side effects like Cushing's disease, necessitating the development of highly selective aldosterone synthase inhibitors with minimal impact on cortisol production.
Innovation Solution
A novel pyranopyridine compound with specific configurations and substituents is developed, exhibiting high selectivity for aldosterone synthase (CYP11B2) while minimizing inhibition of cortisol synthase (CYP11B1), formulated into a pharmaceutical composition for oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If early aldosterone synthase inhibitors are developed, then aldosterone production is inhibited, but cortisol synthesis is also affected due to cross-reaction with CYP11B1
Solution Approach 1:
The patent applies local quality by designing a molecule with distinct functional regions: a core pyranopyridine structure providing CYP11B2 specificity, and specific substituent groups (R1-R6) that fine-tune selectivity. This localized functional differentiation allows the compound to interact preferentially with CYP11B2's unique active site architecture while avoiding cross-reactivity with CYP11B1
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters including the pyranopyridine core configuration, substituent types (halogen, alkyl, alkoxy groups), and their positions on the molecular scaffold. These parameter modifications optimize the compound's steric and electronic properties to achieve high CYP11B2 selectivity with selectivity factors of 50 to 220, effectively decoupling aldosterone inhibition from cortisol suppression
2Reliability
If LCI699 is used as an aldosterone synthase inhibitor, then aldosterone levels decrease, but selectivity for CYP11B2 is insufficient leading to off-target effects
Solution Approach 1:
The patent applies asymmetry by introducing chiral centers and asymmetric substituent patterns on the pyranopyridine core. The non-symmetric molecular architecture creates specific three-dimensional interactions with CYP11B2's asymmetric active site, enhancing selectivity. The asymmetric placement of R1-R6 substituents optimizes binding orientation and affinity for CYP11B2 while reducing off-target effects on CYP11B1 and other enzymes
3Reliability
If MRA is used to antagonize aldosterone, then aldosterone receptor effects are blocked, but off-target side effects occur due to excessive receptor antagonism
Solution Approach 1:
The patent applies the taking out principle by extracting and inhibiting the upstream enzyme (aldosterone synthase CYP11B2) responsible for aldosterone production, rather than blocking the downstream receptor. This upstream inhibition approach selectively reduces aldosterone synthesis at its source without affecting other steroid hormone pathways or causing receptor-mediated off-target effects, providing a more specific therapeutic mechanism
Data Source
AI summary
The invention discloses a pyranopyridine compound, a preparation process, a pharmaceutical composition and use thereof. The present invention provides a compound of Formula (I), a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, which has a strong inhibitory effect on aldosterone synthase, but has little effect on cortisol synthase, is highly selective and has a higher safety, and can be used for preventing and/or treating various diseases associated with aldosterone.